Literature DB >> 23329589

Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?

Afschin Gandjour1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23329589     DOI： 10.1007/s40273-012-0002-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Differences in external price referencing in Europe: a descriptive overview.

Authors:  Christine Leopold; Sabine Vogler; A K Mantel-Teeuwisse; Kees de Joncheere; H G M Leufkens; Richard Laing
Journal:  Health Policy       Date:  2011-10-19       Impact factor: 2.980

2.  The German method for setting ceiling prices for drugs: in some cases less data are required.

Authors:  Afschin Gandjour; Amiram Gafni
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

Review 3.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

4.  Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.

Authors:  Michael Drummond; Bengt Jönsson; Frans Rutten; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2010-08-28

Review 5.  Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

Authors:  Szymon Jarosławski; Mondher Toumi
Journal:  BMC Health Serv Res       Date:  2011-10-08       Impact factor: 2.655
  5 in total
  3 in total

1.  Variations in external reference pricing implementation: does it matter for public policy?

Authors:  Jennifer Gill; Anna-Maria Fontrier; Dionysis Kyriopoulos; Panos Kanavos
Journal:  Eur J Health Econ       Date:  2019-08-23

2.  Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing.

Authors:  Sabine Vogler; Peter Schneider; Nina Zimmermann
Journal:  Pharmacoecon Open       Date:  2019-09

3.  Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors:  Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.